Alexium’s flame-retardant mattress sock passes US flammability testing
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Alexium International Group Limited (ASX:AJX) today announced that prototype foam mattresses using flame retardant (FR) socks treated with Alexiflam® NF have passed flammability testing required by US federal safety standards.
Currently, foam mattresses require a FR sock that is made from glass fibre, which is expensive and comes with environmental and safety risks. Alexium is leveraging its proprietary flame retardant for cotton and cellulose-based textiles, Alexiflam® NF, for application to a cotton/polyester blend mattress sock. The Alexium product will be lower cost and safer than incumbent products.
As regulated by the United States Consumer Product Safety Commission, the testing — conducted by an independent third party, Underwriter Laboratories — confirmed that the barrier treated with Alexiflam® NF met all regulatory requirements (US federal safety standards in 16 CFR 1633) and passed the rigorous flammability test protocol.
Alexiflam® NF technology enables a cotton-based, sustainable and safe solution and removes problematic fiberglass shards out of the bedroom.
Flame-retardant treatments reduce the chances of a fire starting and delay the spread of fire once it starts.
Allen Reihman, Alexium’s Chief Commercial Officer said, “Current FR sock solutions use fiberglass technology to pass fire standards. Consumers are concerned with the health effects of shards of tiny glass that can migrate through the home.”
Mattress suppliers and brands are seeking solutions to this problem, and Alexium looks to have the solution given that socks treated with Alexiflam® NF contain no fiberglass. By treating natural cotton instead of synthetic materials, Alexiflam® NF provides a solution that is both sustainable and safe. Moreover, Alexiflam® NF solutions are more affordable than fiberglass alternatives.
Alexium Chief Executive Officer, Dr Robert Brookins, said “Passing this critical safety test is a major milestone in our commercialisation of Alexiflam® NF and validates our unwavering focus on innovation.”
“We’re progressing according to our growth plan by demonstrating our ability to successfully bring new product solutions to market quickly that align with customer needs. At this stage Alexium will begin working with new and existing customers on how they can use the FR cotton socks in their product lines.”
Today’s announcement follows news in late April that the company had signed a Supply and Evaluation Agreement with Israel Chemicals Ltd (TASE/NYSE: ICL), a leading global specialty minerals and specialty chemicals company, following a long period of co-operation between the two.
Being a major flame retardant chemical company, ICL will act as a strategic business partner for the market launch of Alexiflam® NF.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.